Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
|
|
TherapeuticsMD, Inc. (TXMD)
|
Add to portfolio |
|
|
|
| Price: |
$0.39
| | Metrics |
| OS: |
10.6
|
M
| |
|
|
| Market cap: |
$4.16
|
M
| |
|
|
|
|
|
| |
|
|
|
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
|
|
| |
|
|
|
|
|
| |
|
|
| EPS |
| |
|
|
|
BVPS
|
$2.95
| |
0.13
|
x P/B
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 87.0 | 64.9 | 49.6 | 16.1 | 16.8 | 19.4 | 20.1 | 15.0 |
| Revenue growth | 34.0% | 30.7% | 208.4% | -4.0% | -13.3% | -3.9% | 34.1% | 71.2% |
| Cost of goods sold | 18.8 | 16.0 | 6.3 | 2.7 | 2.6 | 4.2 | 4.5 | 3.7 |
| Gross profit | 68.1 | 48.9 | 43.3 | 13.4 | 14.1 | 15.2 | 15.6 | 11.4 |
| Gross margin | 78.3% | 75.4% | 87.2% | 83.0% | 84.3% | 78.4% | 77.6% | 75.6% |
| Selling, general and administrative | | | | 116.0 | 57.7 | 51.3 | 28.7 | 22.1 |
| Sales and marketing | 108.2 | 117.1 | 114.2 | | | | | |
| Research and development | 7.1 | 10.4 | 19.8 | 27.3 | 33.9 | 53.9 | 72.0 | 43.2 |
| General and administrative | 92.6 | 77.0 | 60.5 | | | | | |
| EBITA | -139.8 | -155.5 | -151.2 | -130.1 | -77.6 | -90.2 | -85.2 | -54.0 |
| EBITA margin | -160.7% | -239.8% | -304.6% | -808.1% | -462.3% | -466.0% | -422.8% | -359.5% |
| Amortization of intangibles | | | | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 |
| EBIT | -139.8 | -155.5 | -151.2 | -130.2 | -77.6 | -90.3 | -85.2 | -54.0 |
| EBIT margin | -160.7% | -239.8% | -304.6% | -808.8% | -462.7% | -466.3% | -422.9% | -359.6% |
| Pre-tax income | -172.4 | -183.5 | -176.1 | -132.6 | -76.9 | -89.9 | -85.1 | -54.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -172.4 | -183.5 | -176.1 | -132.6 | -76.9 | -89.9 | -85.1 | -54.2 |
| Net margin | -198.3% | -282.9% | -354.8% | -823.7% | -458.5% | -464.3% | -422.4% | -360.8% |
| |
| Diluted EPS | ($0.43) | ($0.67) | ($0.72) | ($0.59) | ($0.37) | ($0.46) | ($0.49) | ($0.36) |
| Shares outstanding (diluted) | 398.0 | 275.6 | 246.4 | 225.0 | 205.5 | 196.1 | 173.2 | 149.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|